Cancer Family
Malignant Histiocytic and Dendritic Cell Neoplasm
CI-CAN-00000237Explore in graph →
Hematologic43 active trials1 approved drugs2 evidence items
- NCIt
- C212210
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000237Explore in graph →
Clinical trials
82 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (9)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03386513 | Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN | active not recruiting | Phase 1 / Phase 2 | 179 | AbbVieINDUSTRY | 6 | Sep 4, 2026 | clinicaltrials |
| NCT06690827 | Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCN | recruiting | Phase 1 | 30 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07443137 |
| CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) |
| not yet recruiting |
| Phase 1 |
| 20 |
| Stanford UniversityOTHER |
| 0 |
| Aug 27, 2026 |
| clinicaltrials |
| NCT02159495 | Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm | active not recruiting | Phase 1 | 31 | City of Hope Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04013685 | Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | active not recruiting | Phase 1 | 155 | Orca Biosystems, Inc.INDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05362773 | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | active not recruiting | Phase 1 | 130 | MacroGenicsINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT03113643 | SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | recruiting | Phase 1 | 72 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04318678 | CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) | recruiting | Phase 1 | 108 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT03326921 | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | recruiting | Phase 1 | 24 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT05950802 | Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta(ODIN) | recruiting | Phase 1 | 40 | University Health Network, TorontoOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06712810 | Q702 for the Treatment of Patients With Hematologic Malignancies | recruiting | Phase 1 | 46 | Mayo ClinicOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT05621096 | Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 33 | University of NebraskaOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05476770 | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | recruiting | Phase 1 | 54 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Dec 6, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Sep 4, 2026source: clinicaltrials